Aselizumab  (Synonyms: HuDreg-55)

Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma^[1][2].

Human IgG4 kappa

Human IgG4 kappa, Isotype Control

Humanized

L-selectin^[1][2]

Aselizumab 可与人鼠单克隆 HuDreg-55 轻链二硫化形成二聚体^[1]。
Aselizumab (5-500 ng/mL; 25 分钟) 在冷冻淋巴结切片中阻断人淋巴细胞对高内皮小静脉的 L-选择素依赖性粘附^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Aselizumab (10 mg/kg; 静脉注射; 单次剂量) 在恒河猴中显示出 12.0 天的最终消除半衰期^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

395639-53-9

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Seekamp A, et al. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial. Crit Care Med. 2004 Oct;32(10):2021-8.  [Content Brief]

  [2]. Rahman I, et al. L-selectin regulates human neutrophil transendothelial migration. J Cell Sci. 2021 Feb 8;134(3):jcs250340.  [Content Brief]

  [3]. Co MS, et al. Properties and pharmacokinetics of two humanized antibodies specific for L-selectin. Immunotechnology. 1999 Mar;4(3-4):253-66.  [Content Brief]